As our understanding of cancer has progressed, newer therapies, such as
various targeted therapies and immunotherapy, have become an important part of
today's cancer treatment regimens. This report focuses on pharmacological
therapies - in particular, the pipelines of emerging drugs - for treatment of
solid tumors, discussing:
The various types of solid tumors that are the focus of the most
pharmacological effort, including information about the specific disease, its
incidence and epidemiology, current treatment options, and R&D challenges.
Pipelines of emerging targeted therapies for treatment of solid tumors,
organized by pathway or category.
Business and strategic considerations relating to pharmacological therapy
for solid tumors, including discussions of the current and projected markets,
and market trends.
Major challenges and hurdles for companies developing solid tumor
therapies.
Interviews with experts in the field of solid tumors, which were conducted
exclusively for this report.
Cancer is not a single disease, but includes many different diseases that are
all characterized by the uncontrolled growth and spread of abnormal cells.
Within the broad categories of cancer (such as breast or lung cancer), there
are many different types. And, even within one type of cancer, the molecular
changes that caused the cancer vary with different tumors.
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations
discusses selected major solid tumors that represent the greatest effort by
companies developing new therapies for solid tumors. This report begins with
an initial focus on pharmacological treatment options currently used for the
major solid tumors. While chemotherapy drugs have been used for several
decades, more recently, targeted small-molecule drugs and biological therapies
including monoclonal antibodies have been introduced. This early chapter
discusses all of these therapies.
The major focus of Therapies for Solid Tumors: Pipelines, Markets, and
Business Considerations is on pipelines of emerging drugs for treatment of
solid tumors. Over 80 therapies that have reached Phase III development are
profiled in the body of this report. However, these novel late-stage therapies
only represent the "tip of the iceberg" of new therapies being developed for
treatment of solid tumors. Information regarding emerging therapies in Phase
II or earlier stages of development, plus certain additional Phase III
candidates, is presented in tables. More than 530 companies developing more
than 1,330 new therapies for solid tumors are included in this report.
Biopharmaceutical companies are exploiting hundreds of potential targets or
therapeutic approaches for development of new cancer therapies. The more than
1,330 potential new therapies discussed in this Insight Pharma Report work by
a wide range of mechanisms. Many of these emerging cancer therapies have
multiple mechanisms of action, and are therefore included in multiple tables
within this report.
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations
discusses business strategies relating to development of pharmacological
therapies for solid tumors. This includes an analysis of the current market
and the potential markets for emerging therapies. Also discussed are major
challenges and other tactical considerations for companies working in this
space. This Insight Pharma Report concludes with expert interviews with some
of these companies.
About the Author Lucy J. Sannes, PhD, MBA, is president of Sannes &
Associates, a consulting firm specializing in evaluation and management of the
biosciences. Before forming Sannes & Associates, she held management positions
at Genetic Systems and Abbott Laboratories in product development, product
support, and technical marketing. Dr. Sannes received her PhD in biological
chemistry from the University of Michigan and her MBA from Seattle Pacific
University.
Table of Contents
Table of Contents
Executive Summary
Chapter 1 Introduction
Scope of the Report
Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies
2.1. Brain Cancer
2.2. Breast Cancer
2.3. Cervical Cancer
2.4. Colorectal Cancer
2.5. Head and Neck Cancer
2.6. Lung CancerNon - Small-Cell Lung Cancer
Small-Cell Lung Cancer
2.7. Melanoma
2.8. Ovarian Cancer
2.9. Pancreatic Cancer
2.10. Prostate Cancer
2.11. Renal Cancer
Chapter 3 Current Pharmacological Treatment Options for Solid Tumors
Chapter 4 Selected Emerging Targeted Therapies That Block Cell Growth, Cell Cycle and Replication, DNA Repair, Cell Proliferation, Tumor Invasion, and Metastasis
4.1. Selected Inhibitors of the EGF Receptor Tyrosine Kinase
FamilyBoehringer Ingelheim's Afatinib
CIMAB's, YM Biosciences', and Others' Nimotuzumab
Eli Lilly's and Bristol-Myers Squibb's Necitumumab
Kadmon's KD019
Pfizer's Dacomitinib
Roche/Genentech's PERJETA (Pertuzumab) - Approved June 2012
Roche/Genentech's Trastuzumab Emtansine
4.2. Selected Inhibitors of the Ras-Raf-MEK-ERK PathwayGlaxoSmithKline's
Dabrafenib
GlaxoSmithKline's Trametinib
4.3. Selected Inhibitors of c-MetArQule's, Daiichi Sankyo's, and Kyowa
Hakko Kirin's Tivantinib
Exelixis' Cabozantinib
Roche/Genentech's Onartuzumab
4.4. Selected Inhibitors of Insulin-like Growth Factor (IGF) and
Insulin-like Growth Factor Type 1 Receptor (IGF1R)Amgen's and Takeda
Pharmaceutical's Ganitumab
Table 7.1. Selected Emerging Therapies with Anti-Androgen Activity
Table 7.2. Selected Other Emerging Therapies Targeting Regulation of
Hormones
Table 8.1. Selected Emerging Immunotherapies, Immunomodulators, and
Vaccines for Treatment of Cancer
Table 8.2. Selected Emerging Immunoconjugates for Treatment of Cancer
Table 9.1. Selected Emerging Cytotoxic Drugs in Development for Treatment
of Cancer
Table 10.1. Selected Other Emerging Therapies for Solid Tumors
Table 11.1. Sales of Selected Drugs Used to Treat Solid Tumors
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations - Overview published by Insight Pharma Reports in September 30, 2012. This report price starts from US $ 2495.
